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Clinical mass spectrometry in heart disease
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The presence of mass spectrometry (MS) in
the clinical setting is not a new feature, with
the use of gas chromatography-MS (GC-MS)
for toxicology assays reported as far back as
the 1970s.1 GC-MS is a popular technique
amongst analytical chemists due to the com-
prehensive chemical libraries that have been
generated, and the ability to utilise these
across systems with the use of tools such as
the n-alkane retention index.2 Although there
is no questioning the qualities of GC-MS as an
analytical technique, it owes to troublesome
analysis for clinical samples. Bio-fluid metabo-
lites are required to enter the system in a
volatile state and therefore complicated prepa-
ration involving derivatisation must be per-
formed. On the other hand, liquid chromatog-
raphy-MS (LC-MS) allows for a much simpler
sample preparation of bio-fluid matrices. LC-
MS was a slow mover in the clinical setting,
with many of the early instrumentation seen
as too cumbersome and required experienced
and skilled workers to achieve the desirable
results. Advances in technologies have allowed
increased user versatility and many of the
modern instruments now afford a plug and
play style interface.
Hyphenated mass spectrometric techniques
offer researchers the ability to develop assays
that can analyse multiple target molecules in
one analytical run - an exciting prospect to a
clinician in the view of reducing costs and lead
time for results. In addition, the development
of multiple analyser platforms, such as a triple
quadrupole mass spectrometer (TQ), permits
more selective filtering of molecules, leading
to the ability to detect biomarkers at increas-
ingly lower concentrations. Another feature of
the TQ set up is the ability to improve analyte
identification through tandem mass spectrom-
etry, commonly known as MS/MS. Information
acquired on the intact molecule and its frag-
mentation pattern, after being subject to colli-
sion-inducing energies, is repeatable and thus
aids in identity confirmation. These advances
in LC-MS/MS have led to the analysis of small
molecules that would have previously been
undetectable and allow new biomarkers to be
unearthed.
Early uses of LC-MS in a clinical setting were
to measure acyl carnitines in new born screen-
ing,3 providing a sensitive method to diagnose
deficiencies in fatty acid oxidation. As the
years have progressed, although a mass spec-
trometer has a large financial layout, costs
have reduced and high-throughput, multiplex
assays can be developed, driving the increas-
ing popularity of MS. Additionally to targeted
assays, recent advances in both instrumenta-
tion and statistical softwares have shifted the
focus of biomarker prospecting towards the
global measurement of analytes. Wide-scope,
untargeted analyses carrying the omics tag
have grown in interest and it is now common
to see publications that employ metabolomics
(small molecules) or proteomics (proteins and
peptides) as a tool for novel biomarker discov-
ery. With ever-increasing clinical research lab-
oratories utilising the omics approach and
software packages improving computing
power, multi-centre studies are producing
large sample sets that allow progressively more
reliable definitions to be made. HUPO, the
Human Proteome Organisation, has expressed
an emphasis on the development of an all-
access database with cross-compatible formats
to allow proteomics researchers to share data
and produce a detailed library of the human
proteome.4 
For this editorial, in the instance of cardiovas-
cular disease, we will focus on two recent mass
spectrometric biomarker applications in heart
failure. These are trimethylamine N-oxide
(TMAO), which falls in to the small molecule
section and is a metabolite formed in the liver
by oxidation of trimethylamine, a gut microbe-
generated molecule;5 and b-type natriuretic
peptide (BNP), a peptide biomarker present in
individuals presented with, or at risk of heart
failure.6 To begin, a group of researchers at the
Cleveland Clinic published an article in Nature
in 2011 detailing that plasma TMAO levels
showed association with patients suffering
from coronary heart disease.7 Further research
on this biomarker reported it possessed pro-
atherosclerotic properties,8 and prolonged the
hypertensive effect of angiotensin II.9 When
analysed in a subset of chronic heart failure
patients, elevated levels of TMAO were inde-
pendently predictive of all-cause mortality
within 5 years.10 TMAO is commonly analysed
using stable isotope dilution-LC-MS/MS with
multiple reaction monitoring (MRM). In MRM,
the instrument is tailored to filter a selective
list of ions, perform fragmentation on them
and monitor all reactions in parallel. This
approach allows high levels of sensitivity and
the use of a stable isotope internal standard
vastly improves reproducibility. These analyses
are fast, easy to prepare and robust, and there-
fore lend themselves well to use in a clinical
environment.
Another application of MS used in biomarker
identification is matrix-assisted laser desorp-
tion ionisation-MS, or MALDI-MS. MALDI-MS
allows the accurate mass measurement of
intact protein structures and has been used in
heart failure to measure the degradation prod-
ucts of BNP.11 A downside to using this analyt-
ical method is that often complicated, lengthy
procedures are required to concentrate the
molecule of interest. For the example of BNP,
we recently reported an immunocapture prepa-
ration method that allows sufficient pre-con-
centration of BNP to analysable levels.12 The
raw materials for these types of preparation
methods are often costly, notably for the pur-
chase of suitable antibodies, and analysis itself
can be a time-consuming process. We are cer-
tain that future developments in MS will allow
for these processes to be reduced in complexi-
ty and, therefore, streamlined. Although there
is a list of candidate biomarkers for diagnosis
and prognosis of heart failure, TMAO and BNP
are the only molecules that have shown repeat-
ed research interest using MS-based tech-
niques. Although BNP is measured in the med-
ical setting using an immunoassay, MS-based
analyses are yet to be established as routine
procedures in the clinical laboratory. 
So, the question to be asked is if there is a
space for MS analyses in the clinical laborato-
ry, for the assessment of heart failure, or other
cardiovascular conditions? Our opinion is that
of yes, of course, there is. Research in to TMAO
and BNP look promising, but new metabolomic
and proteomic experiments are regularly being
reported and it is likely that they will produce
new, and more sensitive biomarkers for cardio-
vascular diseases. However, the establishment
of new routinely measured clinical biomarkers
can be a slow process. Clinical decisions
require reliable results and, therefore, the
introduction of new techniques and technolo-
gies requires a level of trust and confidence to
be built. A recent scientific statement released
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by the American Heart Association discusses
several hurdles that must be overcome to
achieve a more secure footing of MS in cardio-
vascular science.13 A main issue raised is the
requirement to improve the communication
between the public, medical and research com-
munities, as with the aforementioned HUPO
proteomic standards initiative. Furthermore,
the need to improve throughput and reliability
of assays, standardisation of protocols and
platforms and implement more widely accept-
ed sample preparation is another note of con-
cern, with many research groups suggesting
their own developed methods. Importantly, the
need for training of MS skills in researchers
and clinical laboratory technicians without
analytical chemistry backgrounds is para-
mount. An interesting point mentioned in the
statement is the value that miniaturisation
will add to the implementation of MS into a
clinical setting. Recent developments of minia-
ture mass spectrometers with direct ambient
ionisation14 show promise to be an exciting
addition to clinical MS in the coming decades.
It is without doubt in our mind that with con-
tinued effort from focussed research groups
we can break the mould of more traditional
assays, and implement our powerful MS-based
analyses into the routine clinical environment.
Perhaps in the future we will be discussing the
next new technology that can out-perform clin-
ical mass spectrometry? We personally believe
that when MS is adapted in to routine screen-
ing, certainly with heart failure, it will be here
to stay.
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